Answer
In MajesTEC-1, nausea was very common with Tecvayli (teclistamab) monotherapy at the recommended regimen, occurring in 45 of 165 adults with multiple myeloma (27%) at any grade, including one patient (0.6%) with grade 3 or 4 nausea.
Sources for this answer
- TECVAYLI 90mg/ml solution for injectionJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.8 Undesirable effects · Version 11Document updated
Sources checked